Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 467

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Receptor for Advanced Glycation End-Products Is a Marker of Type I Cell Injury in Acute Lung Injury

Open access
Uchida, Tokujiro, Shirasawa, Madoka, Ware, Lorraine B., Kojima, Katsuo, Hata, Yutaka, Makita, Koshi, Mednick, Gabe, Matthay, Zachary A., Matthay, Michael A.·2006·American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Receptor for advanced glycation end-products (RAGE) is one of the alveolar type I cell-associated proteins in the lung. OBJECTIVES: To test the hypothesis that RAGE is a marker of alveolar epithelial type I cell injury. METHODS: Rats were instilled intratracheally with 10 mg/kg lipopolysaccharide or hydrochloric acid. RAGE levels were measured in the bronchoalveolar lavage (BAL) and serum in the rats and in the pulmonary edema fluid and plasma from patients with acute lung injury (ALI; n = 22) and hydrostatic pulmonary edema (n = 11). MAIN RESULTS: In the rat lung injury studies, RAGE was released into the BAL and serum as a single soluble isoform sized approximately 48 kD. The elevated levels of RAGE in the BAL correlated well with the severity of experimentally induced lung injury. In the human studies, the RAGE level in the pulmonary edema fluid was significantly higher than the plasma level (p < 0.0001). The median edema fluid/plasma ratio of RAGE levels was 105 (interquartile range, 55-243). The RAGE levels in the pulmonary edema fluid from patients with ALI were higher than the levels from patients with hydrostatic pulmonary edema (p < 0.05), and the plasma RAGE level in patients with ALI were significantly higher than the healthy volunteers (p < 0.001) or patients with hydrostatic pulmonary edema (p < 0.05). CONCLUSION: RAGE is a marker of type I alveolar epithelial cell injury based on experimental studies in rats and in patients with ALI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.200509-1477oc

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 467

Metadata

Authors
Uchida, T., Shirasawa, M., Ware, L. B., Kojima, K., Hata, Y., Makita, K., Mednick, G., Matthay, Z. A., & Matthay, M. A.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2006-05-01
Volume
173
Issue
9
Pages
1008-1015
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2007473062
Cited by
467
References
37
FWCI
10.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Receptor for Advanced Glycation End-Products Is a Marker of Type I Cell Injury in Acute Lung Injury. https://app.cochat.ai/papers/10.1164/rccm.200509-1477oc
The paper
Uchida, T., Shirasawa, M., Ware, L. B., Kojima, K., Hata, Y., Makita, K., Mednick, G., Matthay, Z. A., & Matthay, M. A. (2006). Receptor for Advanced Glycation End-Products Is a Marker of Type I Cell Injury in Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200509-1477oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.